Uptravi For Injection

  • Pulmonary hypertension

Uptravi For Injection Generic Name & Formulations

General Description

Selexipag 1800mcg; per vial; lyophilized pwd for IV infusion after reconstitution and dilution.

Pharmacological Class

Prostacyclin receptor agonist.

See Also

How Supplied

Tabs 200mcg—60, 140; 400mcg, 600mcg, 800mcg, 1000mcg, 1200mcg, 1400mcg, 1600mcg—60; Titration pack—1 (140 x 200mcg tabs) + (60 x 800mcg tabs); Single-dose vial (10mL)—1

Generic Availability


Uptravi For Injection Indications


Pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO functional Class II–III symptoms, to delay disease progression and reduce the risk of hospitalization for PAH, when oral therapy is not feasible.

Uptravi For Injection Dosage and Administration


Give by IV infusion over 80mins twice daily. For corresponding IV dose based on current dose of Uptravi tabs: see full labeling. Moderate hepatic impairment (Child-Pugh class B), concomitant moderate CYP2C8 inhibitors: reduce Uptravi dose to once daily.


Not established.

Uptravi For Injection Contraindications


Concomitant strong CYP2C8 inhibitors (eg, gemfibrozil).

Uptravi For Injection Boxed Warnings

Not Applicable

Uptravi For Injection Warnings/Precautions


Discontinue if pulmonary veno-occlusive disease confirmed. Severe hepatic impairment (Child-Pugh class C): avoid. Pregnancy. Nursing mothers: not recommended.

Uptravi For Injection Pharmacokinetics

See Literature

Uptravi For Injection Interactions


See Contraindications. Potentiated by moderate CYP2C8 inhibitors (eg, clopidogrel, deferasirox, teriflunomide); reduce dosing (see Adults). Antagonized by CYP2C8 and UGT 1A3 or 2B7 inducers (eg, rifampin); increase up to twice the dose.

Uptravi For Injection Adverse Reactions

Adverse Reactions

Headache, diarrhea, nausea, jaw pain, vomiting, pain in extremity, myalgia, flushing, arthralgia, rash, anemia, decreased appetite.

Uptravi For Injection Clinical Trials

See Literature

Uptravi For Injection Note

Not Applicable

Uptravi For Injection Patient Counseling

See Literature